Evidence map›Paper›PMID 42034916›Full record

ArticleScientific reports2026

Enhanced peroxymonosulfate activation for tetracycline removal using magnesium-aluminum layered double hydroxide/zeolitic imidazolate framework-8 nanocomposite.

Zohreh Jalaledin, Ali Akbar Amooey, Shahram Ghasemi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zohreh JalaledinDepartment of Chemical Engineering, Faculty of Engineering and Technology, University of Mazandaran, Babolsar, Iran.
Ali Akbar AmooeyDepartment of Chemical Engineering, Faculty of Engineering and Technology, University of Mazandaran, Babolsar, Iran. aliakbar_amooey@yahoo.com.
Shahram GhasemiFaculty of Chemistry, University of Mazandaran, Babolsar, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced oxidation process (AOP) utilizing peroxymonosulfate (PMS) has emerged as effective methods for environmental remediation due to their high reactivity and selectivity. However, designing hierarchical catalysts with multiple active sites for PMS activation remains an important challenge. Here, a nanocomposite was synthesized based on zeolitic imidazolate framework-8 (ZIF-8) formed on magnesium-aluminum layered double hydroxides (Mg-Al LDH) to facilitate tetracycline (TC) removal through PMS activation. The effects of key operational parameters, including PMS dose, nanocomposite concentration, initial pH, pollutant concentration, and reaction duration, were investigated. The results showed that approximately 97.5% of TC was removed within 12 min at pH = 7, for TC concentration of 25 mg/L, Mg-Al LDH/ZIF-8 dose of 9 mg/L, PMS dose of 0.28 mM. The LDH/ZIF-8/PMS system exhibited superior efficiency for TC removal compared to Mg-Al LDH/ZIF-8, Mg-Al LDH, and ZIF-8. The process was analyzed using Langmuir, Freundlich, and Temkin isotherm models, with the Langmuir model exhibiting the highest correlation coefficient (R2= 0.9923), confirming a monolayer catalytic mechanism on a homogeneous surface. Results from quenching experiments indicated that sulfate and hydroxyl radicals (SO₄•⁻ and •OH) are primary species driving the degradation of TC. These findings provide valuable insights on potential application of Mg-Al LDH/ZIF-8 for environmental purification.

Indexed as

Layered double hydroxideNanocompositePeroxymonosulfateTetracyclineZeolitic imidazolate framework-8

Identifiers

PMID42034916
PMCPMC13284311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.